Yesterday, the FDA (Food and Drug Administration) experts were examining the case of IQOS, the famous Philip Morris heated tobacco system. And to say that the FDA did not hesitate to decide in the strong stating that Philip Morris had not conclusively demonstrated that his device reduced the risk of disease.
If the opinion of the FDA is only advisory and will not necessarily call into question a possible commercialization of the product within a few months, the fact remains that the conclusions revealed remain negative. Indeed, according to the advisory board of the Federal Health Agency (FDA) that met yesterday Philip Morris International should not be allowed to claim that its iQOS heated tobacco device can reduce the risk of smoking-related diseases in smokers who have completely given up smoking.
This committee considers that Philip Morris has not conclusively demonstrated that his device reduces the risk of illness. He also rejected the claim that using this device was less risky than continuing to smoke.
On the other hand, the committee accepted Philip Morris' assertion that iQOS reduces the exposure of its users to harmful or potentially harmful chemicals in smokers who completely quit smoking. However, the tobacco company has not shown that reducing this exposure would reasonably likely result in a measurable and substantial reduction in mortality.
In the meantime, this announcement has had a strong impact on the stock Philip Morris who lost more than 6% before erasing some of his losses and posting a decline of 2,1% at 108,28 dollars at 17h47 GMT on Wall Street . To see if in the coming months the device will obtain a marketing authorization in the United States or not.
source : Boursorama